Hoth Therapeutics' Innovative Antisense Therapy Shows Promise
Innovative Developments in Cancer Treatment Hoth Therapeutics Inc. (NASDAQ: HOTH) has recently shared positive results from its preclinical programs, highlighting the efficacy of their precision antisense candidate HT-KIT. This innovative therapy is specifically designed to target and silence the mutant KIT mRNA. This approach is particularly relevant in treating...
Continue Reading